India apos;s Glenmark To Study Potential COVID-19 Drug Combination

From Open Source Derby
Jump to navigation Jump to search

BENGALURU, May 26 (Reuters) - Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

(Reporting by Sachin Ravikumar, Editing by Sherry Jacob-Phillips)